trial

The Effect of tDCS on Schizophrenia With Negative Symptoms

NCTId NCT03729791
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Withdrawn
Enrollment 0 (actual)
Sponsored by Seoul National University Hospital
Primary completion 2020-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Withdrawn
Enrollment
0 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2019-12-01
Primary completion
2020-12-01
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
TDCS

Sponsors

Seoul National University HospitalLead Sponsor

Investigators

1
Tae Young Lee, MDPrincipal Investigator

Sites

1 total
Seoul, South Korea

Facts & assertions

4 sourced
Enrollment
0
Phase
NA
Primary Completion Date
2020-12-01
Status
WITHDRAWN
relationships
The graph out of here
drug
TDCS
drug
lead_sponsor
Seoul National University Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Tae Young Lee, MD
person